Scott A Armstrong
Overview
Explore the profile of Scott A Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
198
Citations
17592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perner F, Gadrey J, Armstrong S, Kuhn M
Int J Cancer
. 2025 Jan;
PMID: 39887730
Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A-locus at chromosome 11q23...
2.
Gordon S, Perner F, MacPherson L, Wenge D, Bourgeois W, Fennell K, et al.
bioRxiv
. 2024 Dec;
PMID: 39713447
Understanding the molecular pathogenesis of MLL fusion oncoprotein (MLL-FP) leukaemia has spawned epigenetic therapies that have improved clinical outcomes in this often-incurable disease. Using genetic and pharmacological approaches, we define...
3.
Bourgeois W, Armstrong S, Heikamp E
Cold Spring Harb Perspect Med
. 2024 Dec;
PMID: 39694694
Epigenetic therapies are emerging for pediatric cancers. Due to the relatively low mutational burden in pediatric tumors, epigenetic dysregulation and differentiation blockade is a hallmark of oncogenesis in some childhood...
4.
5.
Heikamp E, Martucci C, Henrich J, Neel D, Mahendra-Rajah S, Rice H, et al.
Cell Rep
. 2024 Oct;
43(11):114901.
PMID: 39475509
Control of stem cell-associated genes by Trithorax group (TrxG) and Polycomb group (PcG) proteins is frequently misregulated in cancer. In leukemia, oncogenic fusion proteins hijack the TrxG homolog KMT2A and...
6.
Kwon M, Thuring J, Querolle O, Dai X, Verhulst T, Pande V, et al.
Blood
. 2024 Jun;
144(11):1206-1220.
PMID: 38905635
The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)-altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is...
7.
Smolko A, Sullivan D, Olsen S, Kang H, Whedon S, Baell J, et al.
Proc Natl Acad Sci U S A
. 2024 Jun;
121(26):e2405905121.
PMID: 38889153
Aberrant regulation of chromatin modifiers is a common occurrence across many cancer types, and a key priority is to determine how specific alterations of these proteins, often enzymes, can be...
8.
Waarts M, Mowla S, Boileau M, Martinez Benitez A, Sango J, Bagish M, et al.
Cancer Discov
. 2024 May;
14(10):1860-1878.
PMID: 38819218
Clonal hematopoiesis (CH) is a common premalignant state in the blood and confers an increased risk of blood cancers and all-cause mortality. Identification of therapeutic targets in CH has been...
9.
Chan A, Han L, Delaney C, Wang X, Mukhaleva E, Li M, et al.
Sci Adv
. 2024 Feb;
10(8):eadk3127.
PMID: 38394203
Epigenetic dysregulation has been reported in multiple cancers including leukemias. Nonetheless, the roles of the epigenetic reader Tudor domains in leukemia progression and therapy remain unexplored. Here, we conducted a...
10.
Gu H, Chen C, Hou Z, He X, Xie S, Ni J, et al.
Blood
. 2024 Jan;
143(19):1965-1979.
PMID: 38271660
Acute myeloid leukemia (AML) is an aggressive hematological malignancy originating from transformed hematopoietic stem or progenitor cells. AML prognosis remains poor owing to resistance and relapse driven by leukemia stem...